BioCryst Pharmaceuticals Inc (BCRX)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $1.96B
Last updated: Nov 17, 2026 at 4:51 PM ET
BioCryst Pharmaceuticals Inc (BCRX) Stock Chart
BioCryst Pharmaceuticals (BCRX) has a latest price of $7.50 on Nov 17, 2026, 33.2% below its 52-week high of $11.22. Its price rose 5.9% over the past 12 months. The month-end price rose 109.1% over the 10 years through Oct 2026, a compound annual rate of 7.7%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $16.61 in Feb 2022 and its lowest $2.00 in Oct 2019, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart BCRX with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for BCRX.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 25.5%, and over 6 months it fell 14.5%. The month-end price rose 54.3% over the 3 years through Oct 2026, a compound annual rate of 15.6%.
| Period | Change |
|---|---|
| 1 month | -7.1% |
| 3 months | -25.5% |
| 6 months | -14.5% |
| 12 months | +5.9% |
| 12 months, with dividends | +5.9% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +54.3% | +15.6% |
| 5 years | -43.3% | -10.7% |
| 10 years | +109.1% | +7.7% |
Price by Year
Its best calendar year was 2020, when the price rose 115.9%, and its weakest was 2019, when it fell 57.2%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $8.47 | +8.6% |
| 2025 | $7.80 | +3.7% |
| 2024 | $7.52 | +25.5% |
| 2023 | $5.99 | -47.8% |
| 2022 | $11.48 | -17.1% |
| 2021 | $13.85 | +85.9% |
| 2020 | $7.45 | +115.9% |
| 2019 | $3.45 | -57.2% |
| 2018 | $8.07 | +64.4% |
| 2017 | $4.91 | -22.4% |
Trading Range
The price is 8.0% below its 50-day average of $8.15 and 14.9% below its 200-day average of $8.81.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $7.50 | |
| 52-week high | $11.22 | -33.2% |
| 52-week low | $6.23 | +20.4% |
| 50-day average | $8.15 | -8.0% |
| 200-day average | $8.81 | -14.9% |
Price Risk
Over 3 years, its largest fall from a peak was 46.0%.
| Measure | Value |
|---|---|
| 1-year beta | 0.66 |
| Largest fall, 1 year | -32.9% |
| Largest fall, 3 years | -46.0% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About BCRX
What is BCRX's 1-year price change?
BioCryst Pharmaceuticals's price rose 5.9% over the past 12 months. With dividends included, the 12-month total return was 5.9%.
What is BCRX's 5-year price change?
BioCryst Pharmaceuticals's month-end price fell 43.3% over the 5 years through Oct 2026, a compound annual decline of 10.7%. These figures leave out dividends.
What is BCRX's 52-week high and low?
BioCryst Pharmaceuticals's 52-week high is $11.22 and its 52-week low is $6.23. Its latest price of $7.50 on Nov 17, 2026 is 33.2% below the high.
What is BCRX's beta?
BioCryst Pharmaceuticals's 1-year beta against the S&P 500 is 0.66, so its price has moved less than the market over the past year. Its largest fall from a peak over the past year was 32.9%.
Is the BCRX chart free?
Yes. Advanced Charting for BCRX is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
BCRX pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts